Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Shuttle Pharmaceuticals Holdings's EV-to-OCF or its related term are showing as below:
SHPH'
s EV-to-OCF Range Over the Past 10 Years
Min: -0.18 Med: 0 Max: -0.18
Current: -0.18
During the past 6 years, the highest EV-to-OCF of Shuttle Pharmaceuticals Holdings was -0.18. The lowest was -0.18. And the median was .
SHPH's EV-to-OCF is ranked better than 70.87% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 11.1
vs SHPH: -0.18
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shuttle Pharmaceuticals Holdings's PE Ratio (TTM) for today is calculated as:
Shuttle Pharmaceuticals Holdings's share price for today is $4.33.
Shuttle Pharmaceuticals Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.622.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Shuttle Pharmaceuticals Holdings EV-to-OCF Related Terms
Shuttle Pharmaceuticals Holdings EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shuttle Pharmaceuticals Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shuttle Pharmaceuticals Holdings EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shuttle Pharmaceuticals Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Shuttle Pharmaceuticals Holdings's EV-to-OCF falls into.
Shuttle Pharmaceuticals Holdings's current Enterprise Value is $1.66 Mil.
Shuttle Pharmaceuticals Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shuttle Pharmaceuticals Holdings (SHPH) has a EV-to-OCF of -0.18 as of Aug. 12, 2026. According to the industry distribution chart, Shuttle Pharmaceuticals Holdings ranks #293 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 29.1%.
Is Shuttle Pharmaceuticals Holdings' EV-to-OCF too high?
Shuttle Pharmaceuticals Holdings' current EV-to-OCF is -0.18. Based on the distribution chart, Shuttle Pharmaceuticals Holdings ranks #293 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shuttle Pharmaceuticals Holdings has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Shuttle Pharmaceuticals Holdings' EV-to-OCF compare to PLSH and SKYI?
According to the Drug Manufacturers industry distribution chart, Shuttle Pharmaceuticals Holdings ranks #293 out of 1006 companies for EV-to-OCF. This puts Shuttle Pharmaceuticals Holdings in the upper half of its industry. The industry median EV-to-OCF is 11.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.10, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shuttle Pharmaceuticals Holdings's current EV-to-OCF is -0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shuttle Pharmaceuticals Holdings stock overvalued right now?
Shuttle Pharmaceuticals Holdings (SHPH) has a current EV-to-OCF of -0.18. The current EV-to-OCF is -0.18. Shuttle Pharmaceuticals Holdings' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Shuttle Pharmaceuticals Holdings (SHPH), the current EV-to-OCF is -0.18 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
24GF Score
Get the complete analysis for SHPH
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPH has been successfully added to your 
